ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0138

Alignment and Discordances in Treatment Perceptions and Shared Decision-Making Among RA Patients and Rheumatology Care Teams

Robert Levin1, Christopher Parker2, Kostas Botsoglou3, Jigar Shah4, Nimesh Dayal5, Kristina Fajardo6, Laura Simone6, Jeff Carter6 and Tamar Sapir6, 1University of South Florida, Clearwater, FL, 2Austin Diagnostic Clinic, Austin, TX, 3Rheumatology Center WNY, Buffalo, NY, 4Arthritis and Rheumatology Center of South Florida, Margate, FL, 5Arthritis Center of Orlando, Ocoee, FL, 6PRIME Education, LLC, Fort Lauderdale, FL

Meeting: ACR Convergence 2020

Keywords: education, patient, health behaviors, Patient reported outcomes, quality of care, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Evidence-based guidelines for rheumatoid arthritis (RA) call for shared decision-making (SMD) as a method to personalize treatment decisions and achieve treat-to-target goals. We assessed alignment and discordances on treatment and SDM perceptions among RA patients and their rheumatology care teams.

Methods: Between 09/2019 and 06/2020, surveys were administered to RA patients and their health care professional (HCP) teams as part of in-clinic collaborative patient education sessions across 13 US-based rheumatology community practices. On 5-point Likert scales and multi-select questions, patients and HPs rated or indicated their perceptions, preferences, and concerns regarding RA treatment and SDM.

Results: Surveys were completed by 137 patients with RA (81% female, mean age 57 years) and 41 HCPs (52% physicians, 20% nurse practitioners, 4% physician assistants, 24% nurses) who reported 13 mean years of experience in rheumatology. Alignments were found in patients’ and HCPs’ perceptions of patients’ current level of RA control (well or very well controlled: 50% patients vs 58% HCPs) and satisfaction with current therapy (high or very high: 68% patients vs 65% HCPs).

Discordances were found in patients’ and HCPs’ top goals for RA treatment (Figure 1), which included: prevent joint damage (46% patients, 28% HCPs), achieve remission (42% patients, 20% HCPs), avoid extra-articular manifestations (33% patients, 16% HCPs), improve ability to perform daily tasks (26% patients, 52% HCPs), and minimize therapy side effects (12% patients, 52% HCPs). Discordances were also observed in patients’ and HCPs’ main concerns about targeted therapy for RA (Figure 2), which included potential side effects (54% patients, 42% HCPs), efficacy (46% patients, 17% HCPs), cost (17% patients, 50% HCPs), and monitoring requirements (6% patients, 33% HCPs).

A high proportion of patients and HCPs reported often or always engaging in multiple components of SDM (Figure 3). However, compared with their patients’ responses, HCPs underestimated how often they: explain goals of treatment (80% patients; 65% HCPs), explain disease severity to patients (74% patients; 60% HCPs), and ask patients’ treatment goals, preferences, and concerns (77% patients; 63% HCPs). When asked about the main barrier to SDM, patients reported not knowing enough about RA and available therapies (46%) while HCPs reported perceived patient resistance to SDM (57%).

Conclusion: Identifying alignments and discordances in perceptions of treatment and SDM can support rheumatology teams in individualizing treatment decisions and patient engagement for optimal RA care.


Disclosure: R. Levin, Exagen, 1, 2, Abbvie, 1, 2, Takeda, 1, Sanofi, 1, Janssen, 1, Pfizer, 1, Myriad, 1, 2, Lilly, 1; C. Parker, Amgen, 8, AbbVie, 8; K. Botsoglou, None; J. Shah, Abbvie, 1, GSK, 1, Horizon Pharma, 1, Janssen, 1; N. Dayal, None; K. Fajardo, None; L. Simone, None; J. Carter, None; T. Sapir, None.

To cite this abstract in AMA style:

Levin R, Parker C, Botsoglou K, Shah J, Dayal N, Fajardo K, Simone L, Carter J, Sapir T. Alignment and Discordances in Treatment Perceptions and Shared Decision-Making Among RA Patients and Rheumatology Care Teams [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/alignment-and-discordances-in-treatment-perceptions-and-shared-decision-making-among-ra-patients-and-rheumatology-care-teams/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/alignment-and-discordances-in-treatment-perceptions-and-shared-decision-making-among-ra-patients-and-rheumatology-care-teams/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology